BlueWind Medical news

BlueWind Medical, in preparation for commercialization of the RENOVA product line, announces the hiring of key positions within the organization. Vice President of Sales Mike Ruger, Vice President of Marketing Sandra Muhlfeld, and Vice President of Human Resources Lisa Mead.

BlueWind Medical, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment of Overactive Bladder, today announced additions to its leadership team in preparat

“With the recent completion of enrollment in the OASIS pivotal study, and the potential for FDA marketing clearance in 2023, we are preparing for commercialization and our next phase of corporate growth”, said Dan Lemaitre, Chairman and CEO of BlueWind Medical. “We believe that RENOVA’s minimally invasive and patient centric approach to the treatment of Overactive Bladder will meet the needs of many patients who are disappointed with existing therapies. As a novel ther

Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced it will be participating in the 33rd Annual Virtual Healthcare Conference organized by Piper Sandler on Nov 29th – Dec 2nd, 2021.

As part of the conference, a pre-recorded conversation with Daniel Lemaitre, Chairman and CEO of BlueWind Medical will be available for conference participants. “We appreciate the o

Bluewind Medical, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced it will be participating in the 33rd Annual Virtual Healthcare Conference organized by Piper Sandler on Nov 29th – Dec 2nd, 2021.

As part of the conference, a pre-recorded conversation with Daniel Lemaitre, Chairman and CEO of BlueWind Medical will be available for conference participants. “We appreciate t

Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced the successful completion of patient enrollment in the OASIS pivotal clinical study that will be the basis by which the company will seek US-FDA (Food & Drug Administration) marketing clearance in the United States.

OASIS is a 150-patient prospective clinical study designed to demonstrate the safety and efficacy of Bluew

BlueWind Medical, a medical device company developing minimally invasive neurostimulation devices, announced today the appointment of Kerry Nelson to the company’s Board of Directors. Nelson is a successful medical device investor and fund manager who has launched and managed healthcare focused investment funds. Over the course of her career, she has counseled public and private medical device companies on a range of business strategies from financial planning and investor relations to

Clinical investigators in the OverActive Bladder Stimulation System Study (OASIS) of the RENOVA iStim system, Drs. Becky McCrery and Emily Kean at Adult Pediatric Urology & Urogynecology in Omaha implanted the first U.S. patient in this international clinical study. The RENOVA iStim system is an investigational device designed to reduce urinary urge leakage and improve OAB symptoms. Overactive bladder or OAB, affects millions of women of all ages, and can negatively impact nearly every as

BlueWind Medical announced today that enrollment has commenced at U. S. sites in the Pivotal Clinical Trial of the RENOVA iStim™ implantable tibial neuromodulation System (RENOVA) for the treatment of Overactive Bladder (OAB) following conditional Investigative Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA).

There are approximately 40 million adults in the U.S. alone who experience OAB. OAB affects women of all ages, and can impact quality of life

BlueWind Medical, developer of the RENOVA iStim, an innovative, leadless, miniature neurostimulation platform initially being developed for the treatment of Over Active Bladder (OAB), announced the appointment of Daniel T. Lemaitre as Chief Executive Officer (CEO) effective January 1st, 2020. Mr. Lemaitre has served as Chairman of the Board of BlueWind Medical since November 2018.

Lemaitre is also a board member of Globus Medical and serves as Chairman of Endologix. Previous CEO stint